Multicenter Study of CAOMECS Transplantation to Patients With Total Limbal Stem Cell Deficiency

This study is not yet open for participant recruitment. (see Contacts and Locations)
Verified September 2012 by CellSeed France S.A.R.L.
Sponsor:
Collaborator:
FGK Clinical Research GmbH
Information provided by (Responsible Party):
CellSeed France S.A.R.L.
ClinicalTrials.gov Identifier:
NCT01489501
First received: December 8, 2011
Last updated: September 11, 2012
Last verified: September 2012
  Purpose

This clinical study is a scientific study on patients who do not have any limbal stem cells. In this clinical study tissue is taken from the inside of the mouth, and cells from that tissue (epithelial cells) will be grown to form a multilayered cell-sheet, called CAOMECS, which is then transplanted onto the cornea. This transplantation method should repair the damage of the cornea.

The aim of this study is to see if the transplantation of CAOMECS renews the surface of the eye, by preventing the growth of the conjunctiva over the cornea and stopping new small blood vessels forming.


Condition Intervention Phase
Limbal Stem Cell Deficiency
Procedure: Surgical transplantation of CAOMECS to the ocular surface
Phase 3

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Multicenter Study of Cultured Autologous Oral Mucosal Epithelial Cell-Sheet (CAOMECS) Transplantation to Patients With Total Limbal Stem Cell Deficiency

Resource links provided by NLM:


Further study details as provided by CellSeed France S.A.R.L.:

Primary Outcome Measures:
  • Presence of a stable epithelium on cornea and absence of conjunctivalization in the visual axis [ Time Frame: month 12 ] [ Designated as safety issue: No ]
    This is assessed by delayed fluorescein staining and impression cytology.

  • Extent of neovascularization [ Time Frame: month 12 ] [ Designated as safety issue: No ]
    Measurement of the area of corneal neovascularisation as documented by photographs.


Secondary Outcome Measures:
  • Presence of a stable epithelium on cornea and absence of conjunctivalization in the visual axis [ Time Frame: month 24 and 36 ] [ Designated as safety issue: No ]
    This is assessed by delayed fluorescein staining and impression cytology.

  • Extent of neovascularization [ Time Frame: month 24 and 36 ] [ Designated as safety issue: No ]
    Measurement of the area of corneal neovascularisation as documented by photographs.


Estimated Enrollment: 82
Study Start Date: January 2013
Estimated Primary Completion Date: November 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: only one arm available
Caomecs transplantation on eye cornea.
Procedure: Surgical transplantation of CAOMECS to the ocular surface
Surgical transplantation of oral mucosa derived CAOMECS sheet onto eye cornea.

Detailed Description:

This is an open clinical study without a control group, which means that all patients will be given the study treatment (CAOMECS).

Adults as well as minor patients can participate in this clinical trial.

CAOMECS is undergoing a clinical trial, which means that it has not yet been officially approved for the treatment of this disease. Up to now it was clinically tested in France, on 26 people with limbal stem cell loss.

Study objective

The objective of this study is to restore the ocular surface epithelium of patients with total LSCD by preventing or reducing recurrent conjunctivalization and neovascularization up to 12 months post-transplantation.

Methodology

This is a prospective, open, multi-center study with CAOMECS in patients with total LSCD. Stem cells will be isolated from an oral mucosa biopsy and will be grown in cell culture. The resultant epithelial cell-sheets will then be transplanted to the ocular surface of the respective patients under general anesthesia. After transplantation patients may be hospitalized according to routine clinical practice.

Overall, the study will consist of a screening visit where eligibility will be evaluated, the day of the biopsy, the day before the transplantation where baseline data will be evaluated, the transplantation (day 0), and a follow-up period consisting of nine visits at days 1, 5, and 10 and months 1, 3, 6, 12, 24, and 36. Other visits as clinically indicated may also occur.

  Eligibility

Ages Eligible for Study:   2 Years to 74 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Age ≥2 years to 74 years
  2. Males or females with bilateral or unilateral total LSCD due to one of the following causes:

    1. Chemical burns
    2. Thermal burns
    3. Contact lens wear
    4. Surgery of the ocular surface
    5. Stevens-Johnson syndrome and other inflammatory disease under stable condition
    6. Aniridia
  3. Documented conjunctivalization of the corneal surface, measured by fluorescein staining
  4. Stable disease, i.e. history of LSCD for at least 6 months
  5. Clinical signs indicative of conjunctivalisation:

    1. Superficial blood vessels on the corneal surface
    2. Loss of epithelial transparency or persistent epithelial defect
  6. Healthy oral mucosa
  7. Absence from tobacco and alcohol (7 days before the biopsy)
  8. Regular tooth brushing (at least twice daily)
  9. Ability to comply with the protocol
  10. Covered by a social security system
  11. Signed informed consent form, ability to understand the study procedures, and contractual capability. Applicable to patient or legal carer (including parent)

    Special inclusion criteria for patients between 18 and 74 years of age (adults):

  12. Multiple surgeries in the limbal region

Exclusion Criteria:

  1. Acute systemic infection
  2. Acute ocular inflammation in the previous 6 months
  3. Previous neoplastic/cancer disease
  4. Severe dry eye confirmed by a Schirmer test
  5. Lyell-Syndrome, epidermolysis bullosa
  6. Total symblepharon
  7. Medical history of hypersensitivity or allergy to bovine or murine derived materials
  8. Pregnant and lactating patients, positive urine pregnancy test in women of childbearing potential
  9. Any systemic infectious disease as diagnosed by serology tests such as syphilis, HIV-1, HIV-2, hepatitis B or C, or HTLV-1 infection at screening and at the day of the biopsy
  10. Current or previous (within 30 days of enrolment) treatment with another investigational drug or participation in another clinical study
  11. Previous participation of the patient in this study
  12. Evidence of any other medical conditions (such as psychiatric illness, physical examination or laboratory findings) that may interfere with the planned treatment, affect patient compliance or place the patient at high risk of treatment-related complications
  13. Employees of the sponsor or patients who are employees or relatives of the investigator
  14. Genetic conditions such as ectodermal dysplasia or multiple endocrine neoplasia

    Special exclusion criteria for patients ≥2 and <18 years of age (children):

  15. Multiple surgeries in the limbal region
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01489501

Contacts
Contact: Edgar Fenzl, MD +49-89-893 119 ext 0 info@fgk-cro.com

Locations
Germany
Universitätsklinkum Erlangen Not yet recruiting
Erlangen, Bavaria, Germany, 91054
Contact: Grobauer, PhD    +49 89 893 119 ext 0    info@fgk-cro.com   
Sponsors and Collaborators
CellSeed France S.A.R.L.
FGK Clinical Research GmbH
Investigators
Principal Investigator: Friedrich Kruse, Prof. Dr. Medizinische Fakultät der Friedrich-Alexander-Universität Erlangen-Nürnberg
  More Information

No publications provided

Responsible Party: CellSeed France S.A.R.L.
ClinicalTrials.gov Identifier: NCT01489501     History of Changes
Other Study ID Numbers: CS001-EU01, 2011-000598-30
Study First Received: December 8, 2011
Last Updated: September 11, 2012
Health Authority: Germany: Paul-Ehrlich-Institut

Keywords provided by CellSeed France S.A.R.L.:
Caomecs, Transplantation, Limbal stem cell deficiency,

ClinicalTrials.gov processed this record on September 18, 2014